ELDN earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -4.28. Updated 2026-07-23.
Eledon Pharmaceuticals (ELDN) Research Hub
Eledon Pharmaceuticals (ELDN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.78 USD (-1.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.28, market cap 0.23B. This hub links to the full technical, earnings and options research available for ELDN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.78 USD (-1.42%) |
| 52-week range | 2.75 USD – 4.49 USD |
| Trend regime | Range |
| 14-day RSI | 13.6 (Oversold) |
| Trailing P/E | -4.28 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for ELDN
Covered Call on ELDN: how it works, illustrative setup around the real 2.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ELDN: how it works, illustrative setup around the real 2.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ELDN: how it works, illustrative setup around the real 2.78 USD price, max profit/loss, breakeven and when to use it. Educational.
ELDN technical analysis: range, last 2.78 USD, RSI 13.6, 52w range 2.75 USD–4.49 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ELDN in?
Eledon Pharmaceuticals (ELDN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ELDN in an uptrend or downtrend?
As of 2026-09-11, ELDN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ELDN's trailing P/E ratio?
ELDN's trailing P/E is -4.28, with a market cap of 0.23B. See the earnings research page for full valuation detail.
When does ELDN next report earnings?
ELDN is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.19 USD.